Projections Beat Analyst Targets
The content-services company is spiking higher after projecting 2012 guidance of $0.33 to $0.35 per share, above the $0.30-to-$0.32 range that analysts had been looking for. Management expects revenues of $361 million to $367 million versus the $350.2 million consensus forecast. DMD is up 21.06 percent to $9.60 on my tradeMONSTER platform.
STEC Down on Quarter, Guidance
The data-storage maker is trading sharply lower after missing first-quarter earnings estimates and providing lower guidance on its top and bottom lines. Second-quarter earnings are now estimated at -$0.28 to -$0.26 on revenues of $40 million to $42 million versus previous estimates of -$0.13 EPS and $52.01 million in revenues. STEC is down 12.08 percent to $6.77 this morning.
Dynavax Plunges on Stock Offering
The biopharmaceutical company is falling after announcing plans to sell more stock as it creates a commerical operation to independently launch its HEPLISAV treatment for hepatitis B. The size of the offering was not disclosed. DVAX is down 10.61 percent to $4.30 in pre-market trading.
